Literature DB >> 24456133

Would legalizing illicit opioids reduce overdose fatalities? Implications from a natural experiment.

Shane Darke1, Michael Farrell.   

Abstract

Overdose is the leading cause of premature mortality among heroin users. We examine whether the provision of regulated and quality-controlled heroin to users in specified doses would reduce heroin overdose rates. We also address this in the context of the epidemic of prescription opioid use and deaths seen in recent years in the United States and internationally. We explore the extent to which any change in legal access to heroin would affect overdose rates, and note that this depends upon the validity of the two main assumptions that variations in illicit drug purity and/or the presence of drug contaminants are major causes of overdose. Toxicological and demographic data from studies of heroin overdose deaths do not support these assumptions. The surge in the use of pharmaceutical opioids provides an example of the legal delivery of opioids of known dosage and free of contaminants, where overdose deaths can be examined to test these assumptions. Rates of fatal opioid overdose have escalated, with increased rates of prescribing of pharmaceutical opioids. On the basis of the experience with prescription opioids, unregulated legal heroin access would not reduce overdose rates.
© 2014 Society for the Study of Addiction.

Entities:  

Keywords:  Heroin; legalization; mortality; opioids; overdose; oxycodone

Mesh:

Substances:

Year:  2014        PMID: 24456133     DOI: 10.1111/add.12456

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  7 in total

Review 1.  Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit.

Authors:  Adeleke D Adewumi; Christine E Staatz; Samantha A Hollingworth; Jason P Connor; Rosa Alati
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

2.  The relationship between US heroin market dynamics and heroin-related overdose, 1992-2008.

Authors:  George Unick; Daniel Rosenblum; Sarah Mars; Daniel Ciccarone
Journal:  Addiction       Date:  2014-08-04       Impact factor: 6.526

3.  The effect of prescription opioid injection on the risk of non-fatal overdose among people who inject drugs.

Authors:  Stephanie Lake; Kanna Hayashi; Jane Buxton; M-J Milloy; Huiru Dong; Evan Wood; Julio Montaner; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2015-09-30       Impact factor: 4.492

4.  Prediction of psychiatric comorbidity on premature death in a cohort of patients with substance use disorders: a 42-year follow-up.

Authors:  Mats Fridell; Martin Bäckström; Morten Hesse; Peter Krantz; Sean Perrin; Anna Nyhlén
Journal:  BMC Psychiatry       Date:  2019-05-15       Impact factor: 3.630

5.  Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain.

Authors:  Phillip O Coffin; Christopher Rowe; Natalie Oman; Katie Sinchek; Glenn-Milo Santos; Mark Faul; Rita Bagnulo; Deeqa Mohamed; Eric Vittinghoff
Journal:  PLoS One       Date:  2020-05-04       Impact factor: 3.240

6.  Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time-series analysis.

Authors:  Andrew McAuley; Janet Bouttell; Lee Barnsdale; Daniel Mackay; Jim Lewsey; Carole Hunter; Mark Robinson
Journal:  Addiction       Date:  2016-11-06       Impact factor: 6.526

7.  Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.

Authors:  Anjali K Bhardwaj; David J Allsop; Jan Copeland; Iain S McGregor; Adrian Dunlop; Marian Shanahan; Raimondo Bruno; Nghi Phung; Mark Montebello; Craig Sadler; Jessica Gugusheff; Melissa Jackson; Jennifer Luksza; Nicholas Lintzeris
Journal:  BMC Psychiatry       Date:  2018-05-18       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.